Disseminated intravascular coagulation (DIC) associated with immune checkpoint inhibitor therapy: a real-world study of the FDA adverse event reporting system

View at publisher Summarise with VIRAT
Authors: Xia Yang, Ming Hu, Quanyao Feng, Diwei Mo, Fuzhen Feng, L. Lei, Xingxi Pan
Cited by: 0
References: 29

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

While immune checkpoint inhibitor (ICI)-related adverse effects have gained increasing attention, disseminated intravascular coagulation (DIC) remains understudied. This retrospective study analyzed the FAERS database from 2011 to 2025 using disproportionality analyses to investigate the association between ICIs and immune-mediated DIC. A total of 501 DIC reports associated with ICIs were identified, with male predominance and death as the most frequent serious outcome (276 cases). Anti-CTLA-4 agents, particularly Ipilimumab, exhibited the strongest signal association with DIC. The median time to onset was 23.5 days. Reporting frequency of DIC associated with anti-PD-1/PD-L1 drugs decreased over time, while remaining constant for anti-CTLA-4 agents. This pharmacovigilance analysis identifies a significant signal for DIC following ICI therapy, providing clinicians with critical insights into this potential adverse event and underscoring the need for optimized management to mitigate fatal outcomes.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Pharmacovigilance and Adverse Drug Reactions Heparin-Induced Thrombocytopenia and Thrombosis

Publication details

Journal / source
Journal of Chemotherapy
Pages
1–13
Publication date
30 March 2026
Language
EN